2021 – TNFΑ-DRIVEN INTERPLAY BETWEEN HEMATOPOIETIC STEM CELLS AND ANTIGEN-SPECIFIC CYTOTOXIC T CELLS

IF 2.5 4区 医学 Q2 HEMATOLOGY
Zhiqian Zheng , Akiho Tsuchiya , Emmanuelle Passegué , Atsushi Iwama , Masayuki Yamashita
{"title":"2021 – TNFΑ-DRIVEN INTERPLAY BETWEEN HEMATOPOIETIC STEM CELLS AND ANTIGEN-SPECIFIC CYTOTOXIC T CELLS","authors":"Zhiqian Zheng ,&nbsp;Akiho Tsuchiya ,&nbsp;Emmanuelle Passegué ,&nbsp;Atsushi Iwama ,&nbsp;Masayuki Yamashita","doi":"10.1016/j.exphem.2024.104578","DOIUrl":null,"url":null,"abstract":"<div><p>Clonal expansion of aberrant hematopoietic stem cells (HSCs) underlies many of the hematological disorders. Cells with somatic mutations can be eliminated through presentation of neoantigens on MHC class I to antigen specific CD8+ cytotoxic T lymphocytes (CTL). However, much remains to be elucidated on how HSCs and CTLs interact with each other. Here, we uncover a unique TNFα-driven interplay between HSCs and CTLs. Co-culture and adoptive transfer experiments using ovalbumin-expressing (OVA+) HSCs (Lin-/c-Kit+/Sca-1+/Flk2-/CD48-/CD150+) and OVA-specific OT-I CTLs demonstrated that OVA+ HSCs efficiently present OVA peptide on MHC class I and directly activated OT-I CTLs, making HSCs one of the most susceptible hematopoietic populations to CTL killing. Indeed, adoptive transfer of OT-I CTLs to mixed chimeric mice that harbor both WT and Jak2V617F OVA+ hematopoietic cells specifically eliminated Jak2V617F OVA+ HSC clones and cured myeloproliferative neoplasm. Intracellular FACS analyses revealed that activated OT-I CTLs produced various cytokines including IFNγ and TNFα and HSCs responded to CTL-derived cytokines to upregulate T cell-attracting chemokines such as CXCL9. Interestingly, the response of HSCs to CTL-derived TNFα was critical for CTLs to induce granzyme B, and TNFα receptor–deficient OVA+ HSCs, but not IFNγ receptor–deficient OVA+ HSCs, escaped from OT-I CTL killing. Of note, such response was unique to HSCs and not observed in granulocyte-monocyte progenitors (GMPs: Lin-/c-Kit+/Sca-1-/CD34+/FcγR+). By contrast, prior exposure to TNFα but not IL-1β or IL-6, rendered OVA+ HSCs, but not OVA+ GMPs, resistant to OT-I CTL killing largely through upregulation of PD-L1 and PD-L2. Taken together, our results reveal the robustness of HSC quality control via MHC class I-dependent interplay with CTLs and highlight TNFα as its critical but context-dependent regulator.</p></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"137 ","pages":"Article 104578"},"PeriodicalIF":2.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0301472X24004375/pdfft?md5=46da7ce098574941d68d504e08f9b957&pid=1-s2.0-S0301472X24004375-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301472X24004375","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Clonal expansion of aberrant hematopoietic stem cells (HSCs) underlies many of the hematological disorders. Cells with somatic mutations can be eliminated through presentation of neoantigens on MHC class I to antigen specific CD8+ cytotoxic T lymphocytes (CTL). However, much remains to be elucidated on how HSCs and CTLs interact with each other. Here, we uncover a unique TNFα-driven interplay between HSCs and CTLs. Co-culture and adoptive transfer experiments using ovalbumin-expressing (OVA+) HSCs (Lin-/c-Kit+/Sca-1+/Flk2-/CD48-/CD150+) and OVA-specific OT-I CTLs demonstrated that OVA+ HSCs efficiently present OVA peptide on MHC class I and directly activated OT-I CTLs, making HSCs one of the most susceptible hematopoietic populations to CTL killing. Indeed, adoptive transfer of OT-I CTLs to mixed chimeric mice that harbor both WT and Jak2V617F OVA+ hematopoietic cells specifically eliminated Jak2V617F OVA+ HSC clones and cured myeloproliferative neoplasm. Intracellular FACS analyses revealed that activated OT-I CTLs produced various cytokines including IFNγ and TNFα and HSCs responded to CTL-derived cytokines to upregulate T cell-attracting chemokines such as CXCL9. Interestingly, the response of HSCs to CTL-derived TNFα was critical for CTLs to induce granzyme B, and TNFα receptor–deficient OVA+ HSCs, but not IFNγ receptor–deficient OVA+ HSCs, escaped from OT-I CTL killing. Of note, such response was unique to HSCs and not observed in granulocyte-monocyte progenitors (GMPs: Lin-/c-Kit+/Sca-1-/CD34+/FcγR+). By contrast, prior exposure to TNFα but not IL-1β or IL-6, rendered OVA+ HSCs, but not OVA+ GMPs, resistant to OT-I CTL killing largely through upregulation of PD-L1 and PD-L2. Taken together, our results reveal the robustness of HSC quality control via MHC class I-dependent interplay with CTLs and highlight TNFα as its critical but context-dependent regulator.

2021 - tnfα 驱动造血干细胞与抗原特异性细胞毒性 t 细胞之间的相互作用
异常造血干细胞(HSCs)的克隆扩增是许多血液病的根源。具有体细胞突变的细胞可通过向抗原特异性CD8+细胞毒性T淋巴细胞(CTL)展示MHC I类上的新抗原而被清除。然而,造血干细胞和细胞毒性 T 淋巴细胞之间如何相互作用仍有许多问题有待阐明。在这里,我们发现了造血干细胞和CTL之间独特的TNFα驱动的相互作用。使用表达卵清蛋白(OVA+)的造血干细胞(Lin-/c-Kit+/Sca-1+/Flk2-/CD48-/CD150+)和OVA特异性OT-I CTLs进行的共培养和收养转移实验表明,OVA+造血干细胞能有效地将OVA肽呈现在MHC I类上,并直接激活OT-I CTLs,从而使造血干细胞成为最易被CTL杀伤的造血群体之一。事实上,将 OT-I CTLs 接种到同时携带 WT 和 Jak2V617F OVA+ 造血细胞的混合嵌合小鼠体内,可以特异性地消除 Jak2V617F OVA+ HSC 克隆,并治愈骨髓增生性肿瘤。细胞内 FACS 分析显示,活化的 OT-I CTL 产生了各种细胞因子,包括 IFNγ 和 TNFα,造血干细胞对 CTL 衍生的细胞因子做出反应,上调 T 细胞吸引趋化因子,如 CXCL9。有趣的是,造血干细胞对 CTL 衍生的 TNFα 的反应对 CTL 诱导粒酶 B 至关重要,TNFα 受体缺陷的 OVA+造血干细胞(而非 IFNγ 受体缺陷的 OVA+造血干细胞)可逃脱 OT-I CTL 的杀伤。值得注意的是,这种反应是造血干细胞特有的,在粒细胞-单核细胞祖细胞(GMPs:Lin-/c-Kit+/Sca-1-/CD34+/FcγR+)中未观察到。相比之下,事先暴露于 TNFα 而非 IL-1β 或 IL-6 可使 OVA+ HSCs(而非 OVA+ GMPs)抵抗 OT-I CTL 的杀伤,这主要是通过 PD-L1 和 PD-L2 的上调实现的。综上所述,我们的研究结果揭示了造血干细胞通过 MHC I 类依赖性与 CTL 的相互作用进行质量控制的稳健性,并强调 TNFα 是其关键但依赖于环境的调节因子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Experimental hematology
Experimental hematology 医学-血液学
CiteScore
5.30
自引率
0.00%
发文量
84
审稿时长
58 days
期刊介绍: Experimental Hematology publishes new findings, methodologies, reviews and perspectives in all areas of hematology and immune cell formation on a monthly basis that may include Special Issues on particular topics of current interest. The overall goal is to report new insights into how normal blood cells are produced, how their production is normally regulated, mechanisms that contribute to hematological diseases and new approaches to their treatment. Specific topics may include relevant developmental and aging processes, stem cell biology, analyses of intrinsic and extrinsic regulatory mechanisms, in vitro behavior of primary cells, clonal tracking, molecular and omics analyses, metabolism, epigenetics, bioengineering approaches, studies in model organisms, novel clinical observations, transplantation biology and new therapeutic avenues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信